Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

Market: Pharmaceuticals and Healthcare

Global, 84 pages report, published by GBI Research

Report ThumbnailMay-2017
Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

Summary

The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of crossover between hematological malignancies in terms of their underlying pathophysiology, it is not uncommon for products being devel

Read More
  • 1.2 List of Figures
  • Figure 1: Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987–2015 7
  • Figure 2: Versatile Innovation in Hematological Cancers Therapeutics Market, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval, 2006–2013 ($m) 8
  • Figure 3: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Marketed Product Overvi
Read More
  • 1.1 List of Tables
  • Table 1: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, Forecast 2017 17
  • Table 2: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Commonly Used Chemotherapy Regimens, 2017 20
  • Table 3: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Receptor Neurogenic Locus Notch Homolog Protein 1 as a Molecular Target, 2017 46
  • Table 4: Versatile Innovation
Read More
  • 1 Table of Contents
  • 1 Table of Contents 2
  • 1.1 List of Tables 3
  • 1.2 List of Figures 3
  • 2 Executive Summary 5
  • 2.1 Large Therapy Area with a High Degree of Pathophysiological Crossover 5
  • 2.2 High Degree of First-in-Class Programs and Program Versatility in a Strong Pipeline 5
  • 2.3 Sharp Increase in Deal Activity in Recent Years 5
  • 3 The Case for Innovation in the Hematological Cancer Market 6
  • 3.1 Growing Number of Opportunities for Biologic Products 7
  • 3.2 Diversification of Molecular Targets 7
  • 3.3 Inn
Read More

Related Products

GBI ResearchFrontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile PipelineProduct ThumbnailFrontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline, Industry ReportProduct #: 801619
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2020 Global Market Analyst. All Rights Reserved